Clinical trials: Acute Conditions
Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD…
- Conditions
- Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia, Blast Crisis
- Trial name
- NCT02730312
- Testing
- XmAb14045
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Xencor, Inc.
Pain
Study to Determine Efficacy and Safety of Inhaled AeroLEF in the Treatment of Acute Post-op Pain in Adult Patients Undergoing Elective Orthopedic Surgery
The purpose of this study is to determine the effect of pain relief with AeroLEF in adult patients, following orthopedic surgery.
- Trial name
- NCT00286065
- Testing
- AeroLEF
- Where
- Canada
- Volunteers
- 123 people
- Sponsor
- YM BioSciences
Cerebral Ischemia
Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)
Safety and effect of SANGUINATE on patients DCI following SAH.
- Trial name
- NCT02323685
- Testing
- SANGUINATE™
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Prolong Pharmaceuticals
Coronary Artery Diseases
BIOTRONIK - BIOFLOW-III Registry French Satellite
For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedure success.
- Trial name
- NCT02273648
- Testing
- Drug Eluting Stent (DES)
- Where
- 50 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Biotronik France
ST-elevation MI, Hypothermia
Evaluation of Ultrafast Hypothermia Before Reperfusion in STEMI Patients
This study will look at the safety of treating patients with heart attack with mild hypothermia induced using a system of automated peritoneal lavage.
- Trial name
- VELOCITY (NCT01655433)
- Testing
- Velomedix APLS device, No Hypothermia Treatment
- Where
- 7 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Velomedix, Inc.
AML/MDS, CMML
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination with Azacitidine in Subjects with…
- Conditions
- AML/MDS, CMML, Relapse, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT04139434
- Testing
- LP-108, LP-108 and azacitidine
- Where
- 7 sites in United States, Spain
- Volunteers
- 32 people
- Sponsor
- Newave Pharmaceutical Inc
Acute Lymphoblastic Leukemia, CD19 Positive
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
This is a single center,randomized ,two-cohorts, open-label ,phase 1/2 study to evaluate the efficacy and safety of T cells expressing CD19 chimeric antigen receptors treatment for relapsed/refractory CD19+ acute lymphoblastic…
- Conditions
- Acute Lymphoblastic Leukemia, CD19 Positive, Relapse, Refractory
- Trial name
- NCT03275493
- Testing
- CD19 CAR-T cells, CD19 CAR-T cells with CRS suppression technology
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Healthy, Disease, Chronic
BD MiniDraw™ Capillary System Clinical Equivalence Study
This study designed to evaluate the safety and effectiveness of a newly developed sample collection device. Participants will be enrolled and samples will be collected by representative future users of the device.
- Conditions
- Healthy, Disease, Chronic, Acute Disease, Sample Collection
- Trial name
- NCT05186311
- Testing
- Capillary Blood Collection System
- Where
- United States
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Becton, Dickinson and Company
Acute Coronary Syndrome (ACS)
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in…
- Trial name
- NCT07625306
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the efficacy of GSK2269557 administered in addition to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT02294734
- Testing
- GSK2269557
- Where
- 17 sites in Belgium, Denmark and 3 more
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
- Conditions
- AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia, Refractory Acute Myeloid Leukemia, Hematologic Malignancy
- Trial name
- NCT07014449
- Testing
- WBC100 QD
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hangzhou Weben Pharma Co., Ltd
Coronary Artery Disease, Atherosclerosis, Coronary
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
The objective of this study is to assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic (standard PTCA only) coronary…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease
- Trial name
- BIOFLOW-V (NCT02389946)
- Testing
- Orsiro DES, Xience DES
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Biotronik, Inc.
Coronary Disease, Heart Diseases
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- BIOMAG-III (NCT07258290)
- Testing
- Freesolve RMS, Xience DES
- Where
- 3 sites in United States, Latvia
- Volunteers
- 1,859 people
- Sponsor
- Teleflex
Acute Pain, Surgery
Prospective Observational Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Patients Undergoing Elective Surgical Procedures
The purpose of this study is to evaluate the effect of pharmacogenetics (PGx) guided treatment when implemented into the pre-operative process for patients undergoing bowel surgery, major urologic procedure, or major ventral…
- Trial name
- NCT02605343
- Testing
- NeuroIDgenetix Test Panel
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- AltheaDx
Sprain, Strain
Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury
Imprimis Pharmaceuticals is investigating a proprietary, topical cream formulation consisting of 10% ketoprofen (containing 100 mg of ketoprofen in 1gram of cream) for the local treatment of acute musculoskeletal pain.
- Conditions
- Sprain, Strain, Acute Soft Tissue Injury
- Trial name
- NCT00765700
- Testing
- Topical Ketoprofen 10% Cream
- Where
- United States
- Volunteers
- 364 people
- Sponsor
- Imprimis Pharmaceuticals, Inc.
Gout Flares
A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Initiation of ULT for gout increases the occurrence of acute gouty arthritis flares due to mobilization of urate from tissue deposits. IL-1β plays a key role in mediating the inflammatory response in gouty arthritis.
- Trial name
- NCT01712204
- Testing
- AC-201, Febuxostat
- Where
- Taiwan
- Volunteers
- 82 people
- Sponsor
- TWi Biotechnology, Inc.
Stroke, Cerebral Ischemia
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.
- Conditions
- Stroke, Cerebral Ischemia, Brain Infarction
- Trial name
- NCT00141011
- Testing
- Ancrod (Viprinex)
- Where
- 100 sites in United States, Australia and 8 more
- Volunteers
- 277 people
- Sponsor
- Neurobiological Technologies
Long COVID
Prospective, Open-label Study of Seraph 100 in Patients With Prolonged COVID (PC)
This study will use a prospective, open, single-arm design, in which a group of 100 patients with a diagnosis of prolonged COVID, previously selected according to inclusion and exclusion criteria, and who have undergone informed…
- Trial name
- NCT06637800
- Testing
- Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100)
- Where
- Mexico
- Sponsor
- ExThera Medical Corporation
Obesity
The Acute Effect of Grains of Paradise (Aframomum Melegueta) on REE
Grains of paradise (Aframomumu melegueta) (GP), also known as Guinea pepper or Alligator pepper, belongs to the Zingiberaceae family, which is native to West Africa.
- Trial name
- NCT03894137
- Testing
- Grains of Paradise (Aframomum Melegueta)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Plexus Worldwide
Cerebrovascular Accident
Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients
The purpose of this study is to assess the safety and feasibility of the NeuroFlo™ catheter in treating patients with ischemic stroke whose last time symptom-free was between 8-24 hours prior to treatment.
- Trial name
- Flo 24 (NCT00436592)
- Testing
- NeuroFlo™ Catheter
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 26 people
- Sponsor
- CoAxia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.